Trials / Completed
CompletedNCT01082926
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- City of Hope Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Donor T cells that are treated in the laboratory may be effective treatment for malignant glioma. Aldesleukin may stimulate the white blood cells to kill tumor cells. Combining different types of biological therapies may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best way to give therapeutic donor lymphocytes together with aldesleukin in treating patients with stage III or stage IV malignant glioma.
Detailed description
PRIMARY OBJECTIVES: I. To assess the safety of GRm13Z40-2 CTL CNS loco-regional cellular immunotherapy in research participants with recurrent or refractory/ progressive malignant glioma (WHO Grades 3 or 4). II. To assess the safety of convection enhanced delivery (CED) of recombinant human Interleukin-2 (rhuIL-2) used in conjunction with GRm13Z40-2 CTL adoptive transfer. SECONDARY OBJECTIVES: I. To investigate the ability of 9-(4-fluoro-3-hydroxy-methyl-butyl) guanine (18FHBG) positron emission tomography PET to image GRm13Z40-2 CTL's in research participants. II. To study the impact of concurrent dexamethasone administration on the tempo and magnitude of T cell allograft rejection responses in treated research participants by tracking the frequency of anti-GRm13Z40-2 immune responses in serially acquired peripheral blood samples. III. To evaluate ganciclovir administration for ablating transferred GRm13Z40-2 in vivo should significant graft-mediated toxicities be encountered. OUTLINE: Patients receive GRm13Z40-2 therapeutic allogeneic lymphocytes intratumorally (IT) over 10 minutes on days 1 and 3 and aldesleukin IT over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed annually for at least 15 years.
Conditions
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Meningioma
- Anaplastic Oligodendroglioma
- Brain Stem Glioma
- Ependymoblastoma
- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma
- Grade III Meningioma
- Meningeal Hemangiopericytoma
- Mixed Glioma
- Pineal Gland Astrocytoma
- Brain Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | therapeutic allogeneic lymphocytes | Given intratumorally |
| BIOLOGICAL | aldesleukin | Given intratumorally |
| OTHER | laboratory biomarker analysis | Optional correlative studies |
| PROCEDURE | positron emission tomography | Optional correlative studies |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2010-03-09
- Last updated
- 2015-06-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01082926. Inclusion in this directory is not an endorsement.